MOST COMMON CANCERS
IN CHILDREN
The cancers that dominate adult oncology are essentially absent from pediatric oncology. What pediatric oncologists manage is a completely different list โ arising from embryonic and developmental cell populations.
Pediatric Cancer Types at a Glance
The embryonic origin of most pediatric cancers is precisely why they behave differently, respond differently, and require treatment programmes built specifically for them.
| Cancer Type | Frequency | Key Features | Prognosis |
|---|---|---|---|
| ALL (B-cell and T-cell) | ~25โ30% | Lymphoid progenitor cells; risk stratified by cytogenetics, MRD | Standard-risk >90% cure |
| Brain/CNS tumours | ~25โ30% | Medulloblastoma, low-grade glioma, DIPG โ distinct subtypes | Varies: curable to universally fatal |
| Lymphoma (Hodgkin + NHL) | ~10โ12% | Hodgkin: PD-L1 overexpression; NHL: Burkitt, large B-cell | Hodgkin >90% cure |
| Neuroblastoma | ~7% | MYCN amplification; risk stratification critical | Low-risk: may regress; High-risk: intensive |
| Wilms tumour | ~5% | Embryonic kidney tumour; almost exclusively young children | >90% most stages |
| Rhabdomyosarcoma | ~4% | Embryonal vs alveolar (PAX-FOXO1 fusion); site-dependent | Varies by subtype and stage |
| Bone sarcomas | ~5โ6% | Osteosarcoma + Ewing (EWS-FLI1 fusion); adolescent predominance | Metastatic disease is major adverse factor |
| AML | ~5% | Myeloid progenitor cells; cytogenetic-dependent prognosis | More variable than ALL |
Leukemias: ALL and AML
ALL arises from lymphoid progenitors with cure rates exceeding 90% for standard-risk. High-risk features โ Philadelphia chromosome, MLL rearrangement, hypodiploidy, high MRD โ require treatment intensification and sometimes cellular therapy. AML arises from myeloid progenitors with more variable outcomes. They share the word "leukemia" and bone marrow origin; after that, biology, treatment, and prognosis diverge.
Brain and CNS Tumours
Multiple distinct subtypes with completely different prognoses sharing only anatomical location.
Medulloblastoma
Frequently curable with current multimodal treatment including surgery, craniospinal irradiation, and chemotherapy.
Low-Grade Glioma
Often managed with chemotherapy to delay radiation; indolent course in many patients. BRAF alterations common and targetable.
DIPG / DMG H3K27M
Diffuse midline glioma with H3K27M mutation. Almost universally fatal within 18 months. The most devastating diagnosis in pediatric neuro-oncology.
Embryonic Solid Tumours
Neuroblastoma
Risk stratification divides patients dramatically: low-risk in infants may spontaneously regress without treatment. High-risk with MYCN amplification is among the most intensive treatment experiences in pediatric oncology. Same name, completely different disease.
Wilms Tumour
Embryonic kidney tumour with cure rates above 90% for most stages. Almost exclusively in young children. One of pediatric oncology's greatest treatment successes.
Rhabdomyosarcoma
Prognosis depends on site, histology (embryonal vs alveolar with PAX-FOXO1 fusion), and metastatic status. Alveolar subtype has worse prognosis.
Bone Sarcomas
Osteosarcoma and Ewing sarcoma primarily affect adolescents. Ewing driven by EWS-FLI1 fusion. Both require chemotherapy plus local control. Metastatic disease is a major adverse factor.
Achievements and Remaining Gaps
Cure Rate Achievements
- ALL, Hodgkin lymphoma, Wilms tumour: >90% cure rates
- Built through decades of cooperative group trial refinement
- Advanced therapies (CAR-T) now available for relapsed ALL
Unresolved Challenges
- DIPG remains nearly universally fatal
- High-risk relapsed neuroblastoma: limited effective options
- Metastatic osteosarcoma outcomes unchanged for decades
Frequently Asked Questions
About Childhood Cancer Types
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Understanding Your Child's Diagnosis?
CancerFax helps families understand specific pediatric cancer types and connects them with specialist centres and advanced therapy access.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.